FUM.LSE Futura Medical

Healthcare Pharmaceuticals London Exchange
0.0018 GBX
Close of Nov 3, 2026
0.1595 2.55
Market cap
GBX 2.74M
P/E
-
P/B
1.29x
ROE
-235.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is FUM.LSE undervalued?

Graham number

The Graham number of Futura Medical cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Futura Medical fundamental analysis

No fundamental analysis for Futura Medical yet.

Futura Medical stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Futura Medical

Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical treatment for erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United King…

Full company profile